FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2128701654> ?p ?o ?g. }

• W2128701654 endingPage "1133.e1" @default.
• W2128701654 startingPage "1124" @default.
• W2128701654 abstract "To assess the efficacy and safety of intraocular injections of 0.3 mg or 0.5 mg ranibizumab in patients with macular edema after central retinal vein occlusion (CRVO).Prospective, randomized, sham injection-controlled, double-masked, multicenter clinical trial.A total of 392 patients with macular edema after CRVO.Eligible patients were randomized 1:1:1 to receive monthly intraocular injections of 0.3 or 0.5 mg of ranibizumab or sham injections.The primary efficacy outcome measure was mean change from baseline best-corrected visual acuity (BCVA) letter score at month 6. Secondary outcomes included other parameters of visual function and central foveal thickness (CFT).Mean (95% confidence interval [CI]) change from baseline BCVA letter score at month 6 was 12.7 (9.9-15.4) and 14.9 (12.6-17.2) in the 0.3 mg and 0.5 mg ranibizumab groups, respectively, and 0.8 (-2.0 to 3.6) in the sham group (P<0.0001 for each ranibizumab group vs. sham). The percentage of patients who gained > or =15 letters in BCVA at month 6 was 46.2% (0.3 mg) and 47.7% (0.5 mg) in the ranibizumab groups and 16.9% in the sham group (P<0.0001 for each ranibizumab group vs. sham). At month 6, significantly more ranibizumab-treated patients (0.3 mg = 43.9%; 0.5 mg = 46.9%) had BCVA of > or = 20/40 compared with sham patients (20.8%; P<0.0001 for each ranibizumab group vs. sham), and CFT had decreased by a mean of 434 microm (0.3 mg) and 452 microm (0.5 mg) in the ranibizumab groups and 168 microm in the sham group (P<0.0001 for each ranibizumab group vs. sham). The median percent reduction in excess foveal thickness at month 6 was 94.0% and 97.3% in the 0.3 mg and 0.5 mg groups, respectively, and 23.9% in the sham group. The safety profile was consistent with previous phase III ranibizumab trials, and no new safety events were identified in patients with CRVO.Intraocular injections of 0.3 mg or 0.5 mg ranibizumab provided rapid improvement in 6-month visual acuity and macular edema following CRVO, with low rates of ocular and nonocular safety events." @default.
• W2128701654 created "2016-06-24" @default.
• W2128701654 creator A5027224484 @default.
• W2128701654 creator A5030449236 @default.
• W2128701654 creator A5056360633 @default.
• W2128701654 creator A5061664536 @default.
• W2128701654 creator A5063622809 @default.
• W2128701654 creator A5065814663 @default.
• W2128701654 creator A5085213833 @default.
• W2128701654 creator A5085965174 @default.
• W2128701654 creator A5089896434 @default.
• W2128701654 date "2010-06-01" @default.
• W2128701654 modified "2023-09-30" @default.
• W2128701654 title "Ranibizumab for Macular Edema following Central Retinal Vein Occlusion" @default.
• W2128701654 cites W1565832645 @default.
• W2128701654 cites W1898187276 @default.
• W2128701654 cites W1964376024 @default.
• W2128701654 cites W1968746974 @default.
• W2128701654 cites W1977995451 @default.
• W2128701654 cites W1980739272 @default.
• W2128701654 cites W1983422848 @default.
• W2128701654 cites W1998806479 @default.
• W2128701654 cites W2015775567 @default.
• W2128701654 cites W2054551550 @default.
• W2128701654 cites W2055741851 @default.
• W2128701654 cites W2061463978 @default.
• W2128701654 cites W2065142041 @default.
• W2128701654 cites W2068100937 @default.
• W2128701654 cites W2073337868 @default.
• W2128701654 cites W2085712747 @default.
• W2128701654 cites W2092011198 @default.
• W2128701654 cites W2124415048 @default.
• W2128701654 cites W2133150079 @default.
• W2128701654 cites W2142651474 @default.
• W2128701654 cites W2154763327 @default.
• W2128701654 cites W2168451815 @default.
• W2128701654 cites W2324588265 @default.
• W2128701654 cites W2993769995 @default.
• W2128701654 cites W4233230329 @default.
• W2128701654 cites W4235001346 @default.
• W2128701654 cites W4239471829 @default.
• W2128701654 cites W4242731554 @default.
• W2128701654 cites W4245223880 @default.
• W2128701654 cites W4246878943 @default.
• W2128701654 cites W4247664461 @default.
• W2128701654 cites W4250416245 @default.
• W2128701654 cites W4297755600 @default.
• W2128701654 doi "https://doi.org/10.1016/j.ophtha.2010.02.022" @default.
• W2128701654 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20398941" @default.
• W2128701654 hasPublicationYear "2010" @default.
• W2128701654 type Work @default.
• W2128701654 sameAs 2128701654 @default.
• W2128701654 citedByCount "891" @default.
• W2128701654 countsByYear W21287016542012 @default.
• W2128701654 countsByYear W21287016542013 @default.
• W2128701654 countsByYear W21287016542014 @default.
• W2128701654 countsByYear W21287016542015 @default.
• W2128701654 countsByYear W21287016542016 @default.
• W2128701654 countsByYear W21287016542017 @default.
• W2128701654 countsByYear W21287016542018 @default.
• W2128701654 countsByYear W21287016542019 @default.
• W2128701654 countsByYear W21287016542020 @default.
• W2128701654 countsByYear W21287016542021 @default.
• W2128701654 countsByYear W21287016542022 @default.
• W2128701654 countsByYear W21287016542023 @default.
• W2128701654 crossrefType "journal-article" @default.
• W2128701654 hasAuthorship W2128701654A5027224484 @default.
• W2128701654 hasAuthorship W2128701654A5030449236 @default.
• W2128701654 hasAuthorship W2128701654A5056360633 @default.
• W2128701654 hasAuthorship W2128701654A5061664536 @default.
• W2128701654 hasAuthorship W2128701654A5063622809 @default.
• W2128701654 hasAuthorship W2128701654A5065814663 @default.
• W2128701654 hasAuthorship W2128701654A5085213833 @default.
• W2128701654 hasAuthorship W2128701654A5085965174 @default.
• W2128701654 hasAuthorship W2128701654A5089896434 @default.
• W2128701654 hasConcept C118487528 @default.
• W2128701654 hasConcept C126322002 @default.
• W2128701654 hasConcept C141071460 @default.
• W2128701654 hasConcept C168563851 @default.
• W2128701654 hasConcept C2776694085 @default.
• W2128701654 hasConcept C2777802072 @default.
• W2128701654 hasConcept C2778257484 @default.
• W2128701654 hasConcept C2778844676 @default.
• W2128701654 hasConcept C2780347916 @default.
• W2128701654 hasConcept C2781100027 @default.
• W2128701654 hasConcept C44249647 @default.
• W2128701654 hasConcept C71924100 @default.
• W2128701654 hasConceptScore W2128701654C118487528 @default.
• W2128701654 hasConceptScore W2128701654C126322002 @default.
• W2128701654 hasConceptScore W2128701654C141071460 @default.
• W2128701654 hasConceptScore W2128701654C168563851 @default.
• W2128701654 hasConceptScore W2128701654C2776694085 @default.
• W2128701654 hasConceptScore W2128701654C2777802072 @default.
• W2128701654 hasConceptScore W2128701654C2778257484 @default.
• W2128701654 hasConceptScore W2128701654C2778844676 @default.
• W2128701654 hasConceptScore W2128701654C2780347916 @default.
• W2128701654 hasConceptScore W2128701654C2781100027 @default.
• W2128701654 hasConceptScore W2128701654C44249647 @default.

• next